The pathophysiology of COVID-19 causing GBS involves SARS-CoV-2 using angiotensin-converting enzyme 2 (ACE-2) receptors to enter host cells, affecting the lungs, gastrointestinal tract, cardiomyocytes, urothelial cells, and proximal tubular cells [11]. This evidence concerns the gene ACE2 and Guillain-Barre syndrome.